Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 11/20 | 0.37 |
| ▸ | HEXB | P07686 | 2/20 | 0.37 |
| ▸ | HEXA | P06865 | 1/20 | 0.37 |
| ▸ | PYGB | P11216 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26893427 | 0.80 | LGALS1 (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL23705204 | 0.80 | LGALS1 (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL26698792 | 0.80 | LGALS1 (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL14421336 | 0.69 | ALDH1A1 (0.39) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL5444302 | 0.68 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL24243426 | 0.68 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL15370355 | 0.68 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL5444368 | 0.68 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL5446587 | 0.68 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL5444372 | 0.68 | LGALS1 (0.59) | LGALS1LGALS3LGALS9LGALS8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LGALS1 114/4885LGALS3 240/4885LGALS9 276/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | LGALS1 126/4885LGALS3 435/4885LGALS9 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.